Chugai ( Chugai)

Primary tabs

Chugai's picture

Management

Contact Address

About Chugai

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

Chugai press release, blog etc

Tue, 05/20/2025 - 15:39 Chugai Obtains First Regulatory Approval in Japan for Vabysmo for Additional Indication of Angioid Streaks, a Cause of Vision Loss
Tue, 05/13/2025 - 06:46 Chugai Receives Regulatory Approval for ELEVIDYS as a Gene Therapy Product for Duchenne Muscular Dystrophy in Japan
Fri, 03/28/2025 - 05:45 Joint Research Results on Regulatory T cells between Osaka University Immunology Frontier Research Center and Chugai Published in Nature
Thu, 03/27/2025 - 04:51 Chugai Obtains Regulatory Approval for First Tablet for SMA, Evrysdi
Tue, 03/18/2025 - 21:51 Chugai Launches LUNSUMIO for Intravenous Infusion, a Bispecific Antibody for Relapsed or Refractory Follicular Lymphoma in Japan
Thu, 02/20/2025 - 05:57 Chugai Obtains Regulatory Approval for Tecentriq for the Additional Indication of Alveolar Soft Part Sarcoma, an Ultra-rare Disease
Thu, 01/30/2025 - 05:15 Chugai and GSK Sign Collaboration Agreement for Anti-Dengue Virus Antibody AID351
Fri, 01/17/2025 - 05:27 Chugai Wins the MHLW Ministers Award at the Seventh Japan Medical Research and Development Grand Prize for the Discovery of an ALK-Positive Lung Cancer Treatment Alecensa
Mon, 12/16/2024 - 13:39 Personalized cancer treatment The Launch of Chugais New TV Commercial Featuring Tori Matsuzaka Innovation Lab / Cancer Genomic Medicine
Wed, 08/28/2024 - 05:10 Transfer and Future Marketing of Secondary Hyperparathyroidism Drug OXAROL for Injection in Japan
Wed, 08/28/2024 - 05:10 Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Wed, 08/14/2024 - 06:45 Chugai Files Elevidys (SRP-9001) as a Gene Therapy Product for Duchenne Muscular Dystrophy in Japan
Fri, 08/09/2024 - 08:21 Chugai Continues to be Listed for All ESG Indices Adopted by GPIF
Wed, 08/07/2024 - 07:51 Chugai In-Licenses Anti-TL1A Antibody RG6631 for the Intractable Diseases Ulcerative Colitis and Crohns Disease
Fri, 08/02/2024 - 16:21 Chugais Alecensa Approved in Taiwan as an Adjuvant Treatment for Early Stage ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Mon, 07/22/2024 - 15:45 Transfer and Future Marketing of Physiological Intestinal Function Improving and Hyperammonemia Drug MONILAC Syrup 65% in Japan
Mon, 06/10/2024 - 19:59 Alecensa Approved by the European Commission as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer
Thu, 02/08/2024 - 23:01 Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
more

InfoBox

HomePagewww.chugai-pharm.co.jp
Twittertwitter.com/chugai_cc
Wikipediaen.wikipedia.org/wiki/Chugai_Pharmaceutical_Co.